Ropes and Gray: Vir Biotechnology Enters Collaboration With Gilead Sciences Aimed at Solid Tumors Worth Up to $1.9 Billion
October 16, 2026
October 16, 2026
BOSTON, Massachusetts, Oct. 16 -- Ropes and Gray, a law firm, issued the following news:
* * *
Vir Biotechnology Enters Collaboration with Gilead Sciences Aimed at Solid Tumors Worth up to $1.9 Billion
October 15, 2026
Ropes & Gray advised Vir Biotechnology in a collaboration and license agreement with Gilead Sciences to discover and engineer three novel next-generation dual-masked T-cell engager candidates targeting selected solid tumor-as . . .
* * *
Vir Biotechnology Enters Collaboration with Gilead Sciences Aimed at Solid Tumors Worth up to $1.9 Billion
October 15, 2026
Ropes & Gray advised Vir Biotechnology in a collaboration and license agreement with Gilead Sciences to discover and engineer three novel next-generation dual-masked T-cell engager candidates targeting selected solid tumor-as . . .